Intelligence / Healthtech / De Novo Grants / Theraclion SA
Approvalsnovel device granted (FDA De Novo)4 Nov 2026
Theraclion SA
4 Nov 2026: Novel device granted (FDA De Novo) · Sonovein System. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 4 Nov 2026
- Device
- Sonovein System
- Specialty
- Not stated
- Product Code
- SJR
- Country
- France
- Location
- Malakoff, France
- Submitted
- 2025-12-08
- Reference
- DEN250063
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Theraclion SA
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Theraclion SA in our registers.
More in Not stated
De Novo Grants
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.